Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Better Patient Selection Needed for AML Therapies

November 30th 2017

Alexander E. Perl, MD, discusses the future of FLT3 inhibitors, current obstacles with treating patients with acute myeloid leukemia, and what pivotal trial results the community can expect to hear in the coming months.

FDA Grants Mogamulizumab Priority Review for CTCL

November 28th 2017

The FDA has granted a priority review to a biologics license application for mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.

Dr. Young on the Challenges of Using Anticoagulants in Children With Cancer

November 28th 2017

Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, discusses the challenges of using anticoagulants in children with cancer.

Dr. Gordon on the Role of Checkpoint Inhibitors in Hematologic Malignancies

November 21st 2017

Leo I. Gordon, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, discusses the role of checkpoint inhibitors for patients with hematologic malignancies.

Nilotinib Approved in Europe for Subset of Pediatric CML

November 21st 2017

The European Commission has approved nilotinib (Tasigna) for the treatment of pediatric patients with Ph+ chronic myeloid leukemia in the chronic phase.

Dr. Winter Discusses Copanlisib in Follicular Lymphoma

November 18th 2017

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses copanlisib (Aliqopa) in follicular lymphoma.

MRD, Genetic Classification Provide More Accurate Risk Stratification in Pediatric ALL

November 17th 2017

Investigators working in the UK and Europe found a correlation between minimal residual disease kinetics and risk for relapse in pediatric patients with acute lymphoblastic leukemia.

FDA Grants BCMA CAR T-Cell Therapy Breakthrough Designation in Myeloma

November 17th 2017

The FDA has granted the the anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy bb2121 a breakthrough therapy designation for previously treated patients with relapsed/refractory multiple myeloma.

FDA Approves Frontline Obinutuzumab for Follicular Lymphoma

November 16th 2017

The FDA has approved obinutuzumab (Gazyva) in combination with chemotherapy, followed by obinutuzumab alone, for the first-line treatment of patients with advanced follicular lymphoma.

CAR T-Cell Therapy Approval Starts New Path in Childhood Leukemia

November 16th 2017

Sarah K. Tasian, MD, discusses the success of CAR T-cell therapy, as well as novel agents and immunotherapies that appear promising in the treatment of children with leukemia.

Dr. Daver on CAR T-Cell Therapy Approval in Pediatric ALL

November 16th 2017

Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the approval of a chimeric antigen receptor (CAR) T-cell therapy in pediatric acute lymphoblastic leukemia.

Dr. Stone on Monitoring Patients With AML

November 15th 2017

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring patients with acute myeloid leukemia.

Brentuximab Vedotin Nears European Approval for CTCL

November 15th 2017

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of brentuximab vedotin (Adcetris) in adults with CD30-positive cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

Umbralisib, Ublituximab, Ibrutinib Triplet Reaches 100% Response in CLL

November 14th 2017

Loretta J. Nastoupil, MD, discusses the study of the triplet of ublituximab, umbralisib (TGR-1202) and ibrutinib in CLL.

Acalabrutinib Among Exciting Options Emerging in CLL

November 14th 2017

Jacqueline Claudia Barrientos, MD, discusses emerging treatment options in CLL.

Dr. Mims Discusses Momelotinib in Myelofibrosis

November 10th 2017

Alice S. Mims, MD, assistant professor of medicine, The Ohio State University Comprehensive Cancer Center, discusses momelotinib in patients with myelofibrosis.

FDA Approves Dasatinib for Pediatric Ph+ Chronic Phase CML

November 10th 2017

The FDA has approved dasatinib (Sprycel) for the treatment of pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

Dr. Shah on Toxicites Associated With CAR T-Cell Therapy

November 10th 2017

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, comments on the toxicities associated with using chimeric antigen receptor (CAR) T-cell therapy in patients with leukemia.

FDA Approves Brentuximab Vedotin for CTCL

November 10th 2017

The FDA has approved brentuximab vedotin (Adcetris) as a treatment for patients with cutaneous T-cell lymphoma who have received prior systemic therapy.

Refining Role of Brentuximab Vedotin and Immunotherapy in Hodgkin Lymphoma

November 9th 2017

As clinicians’ understanding of the disease pathobiology associated with Hodgkin lymphoma (HL) has increased, novel treatments have emerged.